Literature DB >> 2060129

The clinical significance of cyclosporine metabolites.

R W Yatscoff1, T G Rosano, L D Bowers.   

Abstract

Cyclosporine (CsA) is extensively metabolized, with over 14 metabolites having been characterized to date. The confirmation of structure and purity is a prerequisite for studies involving CsA metabolites. Analytical techniques such as fast atom bombardment/mass spectroscopy (FAB/MS), tandem mass spectrometry (MS), 1H- and 13C-nuclear magnetic resonance (NMR) can be used for such purposes. In vitro experiments indicate that metabolites are considerably less immunosuppressive and toxic than CsA. In vivo studies have been hampered by sufficient quantities of metabolites and a suitable animal model. Preliminary results in the rat suggest that CsA metabolites are less immunosuppressive and toxic than CsA, although these results must be confirmed using a more suitable animal model. Present data indicate that the routine monitoring of metabolites is not warranted in transplant patients, although additional information is required to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060129     DOI: 10.1016/0009-9120(91)90126-y

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 3.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

4.  In vitro metabolism of cyclosporin A with rabbit renal or hepatic microsomes: analysis by HPLC-FPIA and HPLC-MS.

Authors:  C Pham-Huy; N Sadeg; T Becue; C Martin; G Mahuzier; J M Warnet; M Hamon; J R Claude
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

5.  Validation of a novel UPLC-HRMS method for human whole-blood cyclosporine and comparison with a CMIA immunoassay.

Authors:  Xiaoxue Wang; Wei Qin; Wenqian Chen; Huifang Liu; Dan Zhang; Xianglin Zhang; Pengmei Li
Journal:  Exp Ther Med       Date:  2021-01-07       Impact factor: 2.447

6.  Comparison of architect I 2000 for determination of cyclosporine with axsym.

Authors:  Nafija Serdarevic; Lejla Zunic
Journal:  Acta Inform Med       Date:  2012-12

7.  Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region.

Authors:  Xuzhen Qin; Jianzhong Rui; Yong Xia; Hong Mu; Sang Hoon Song; Raja Elina Raja Aziddin; Gabrielle Miles; Yuli Sun; Sail Chun
Journal:  Ann Lab Med       Date:  2018-03       Impact factor: 3.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.